Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Gross Margin: 2012-2025

Historic Gross Margin for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to 86.96%.

  • Agios Pharmaceuticals' Gross Margin fell 430.00% to 86.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 87.22%, marking a year-over-year decrease of 216.00%. This contributed to the annual value of 88.59% for FY2024, which is 67.00% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Gross Margin stood at 86.96% for Q3 2025, which was up 0.73% from 86.33% recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Gross Margin ranged from a high of 92.34% in Q1 2024 and a low of 59.25% during Q1 2022.
  • Moreover, its 3-year median value for Gross Margin was 88.26% (2024), whereas its average is 88.38%.
  • The largest annual percentage gain for Agios Pharmaceuticals' Gross Margin in the last 5 years was 3,087bps (2023), contrasted with its biggest fall of 871bps (2023).
  • Quarterly analysis of 4 years shows Agios Pharmaceuticals' Gross Margin stood at 90.42% in 2022, then soared by 133bps to 91.75% in 2023, then slumped by 349bps to 88.26% in 2024, then slumped by 430bps to 86.96% in 2025.
  • Its last three reported values are 86.96% in Q3 2025, 86.33% for Q2 2025, and 87.57% during Q1 2025.